TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07213778: A Phase 3, Multicenter, Double-Blinded, Randomized Study to Evaluate REGN7508, a Factor XI Monoclonal Antibody, Versus Acetylsalicylic Acid for Prophylaxis of Symptomatic Venous Thromboembolism After Elective Total Knee

Sponsor: Regeneron Pharmaceuticals · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 2000 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$4,667,256

Rescue Site Savings

+$3,064,360

Unlock Full NCT07213778 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07213778 Rescue Dossier →